In early-mid November 2021, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for two new cardiovascular technologies (Revivent TC™ by BioVentrix and Trilogy™ Heart Valve System by JenaValve Technology) in heart failure, and aortic valve insufficiency and stenosis, respectively.
The decision to initiate the evaluation of transvascular, transcatheter-supported implantation of an aortic valve for the treatment of aortic valve insufficiency and stenosis (Trilogy™ Heart Valve System by JenaValve Technology), within the framework of the early benefit assessment in accordance with § 137h SGB V was made by the G-BA on November 8, 2021.
On November 15, 2021, the same decision was made by the G-BA for minimally invasive, left ventricular reconstruction using an anchoring system in heart failure (Revivent TC™ by BioVentrix).
This evaluation is a consequence of the application by a hospital for Innovation Funding (NUB), a short-term, intermediate reimbursement for new and innovative technologies in Germany.
The full details in German can be found here and here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.